ClinicalTrials.gg

Program

JL18008

A development code. Also written as “JL18008 20 μg/kg”, “JL18008 40 μg/kg” and “JL18008 70 μg/kg”.

Its studies are mostly in HIV Infections, led by Jecho Biopharmaceuticals.

Furthest: phase 2, since Apr 21, 20263 company-led studies, 2 open or runningNext primary completion: Feb 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jecho Biopharmaceuticals32 open or runningphase 2since Apr 21, 2026Jan 29, 2026Feb 12, 2027phase 2 · NCT07579741

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2026First study: phase 1 study in HIVFirst studyNCT07443228 · 52 planned
  2. Apr 21, 2026Phase 2 study in HIV InfectionsPhase 2 reachedNCT07579741 · 30 planned · China
  3. May 21, 2026Phase 1 study in HIV InfectionsNCT07629310 · 40 enrolled · China

Ahead

  1. Feb 12, 2027Primary completion: phase 2 study in HIV InfectionsNCT07579741
  2. Dec 20, 2029Primary completion: phase 1 study in HIVNCT07443228

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07629310HIV Infections · China1CompletedAug 5, 202540
NCT07579741HIV Infections · China2RecruitingFeb 12, 202730
NCT07443228HIV1Not yet recruitingDec 20, 202952

How it is read

Names in the registry

  • “JL18008 20 μg/kg”, 2 entries
  • “JL18008 40 μg/kg”, 2 entries
  • “JL18008 70 μg/kg”, 2 entries
  • “JL18008 1 μg/kg”, 1 entry
  • “JL18008 5 μg/kg”, 1 entry

Codes read as this program: JL18008.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.